Occurrence of tuberculous pleurisy associated with infliximab therapy.
- Author:
Young Seok LEE
1
;
Jae One JUNG
;
Ji Hyun HONG
;
Young Il SEO
;
Kwang Seok EOM
;
Seung Hun JANG
;
Ki Suck JUNG
Author Information
1. Department of Internal Medicine, Hallym University Sacred Heart Hospital, College of Medicine, Hallym University, Anyang, Korea. pulmoks@hallym.ac.kr
- Publication Type:Case Report
- Keywords:
TNF-alpha;
Infliximab;
Tuberculosis
- MeSH:
Humans;
Latent Tuberculosis;
Spondylitis, Ankylosing;
Tuberculosis;
Tuberculosis, Pleural*;
Tumor Necrosis Factor-alpha;
Infliximab
- From:Korean Journal of Medicine
2004;67(4):421-424
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
Infliximab is a chimeric antibody against tumor necrosis factor-alpha and it can be used in the treatment of ankylosing spondylitis. Tumor necorosis factor-alpha is a potent proinflammatory cytokine and plays a key role in the host response against tuberculosis. Infliximab is known to be effective on active ankylosing spondylitis but it can also cause reactivation of latent tuberculosis. Physicians should screen patients for latent tuberculous infection or disease before prescribing the drug. We experienced a case of tuberculous pleurisy after taking infliximab in a patient suffering from ankylosing spondylitis. We present the case with a review of literature.
